Bli medlem
Bli medlem

Du är här


BioStock: WntResearch's CEO on the option program and the NeoFox study

The development company WntResearch is currently in the process of redeeming the TO5 warrant. The capital injection is made to continue the phase IIb study with the drug candidate Foxy-5. In connection with the BioStock Investor Meeting, the company's CEO Pernilla Sandwall talked about the option program, changes in the study plan and the outcome of the company's issue.

Watch the full video interview with Pernilla Sandwall at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision